1McArdle P. Intravenous analgesia. Crit Care Clin, 1999,15:89-104.
2Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anesthesia. Drug Saf, 1998,19:173-189.
3Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia"in postoperative pain treatment. Anesth Analg, 1993,77:1048-1056.
4Power I, Barrett S. Analgesic agents for the postoperative period: nonopioids. Surg Clin North Am, 1999,79:275-295.
5Tong D, Chung F. Postoperative pain control in ambulatory surgery. Surg Clin North Am, 1999,79:401-430.
6Lipsky LP, Abramson SB, Crefford L, et al. The classification of cyclooxygenase inhibitors. J Rheumatol, 1998,25:2298-2303.
7Penning TD, Talley JJ, Berteushaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenuse-2 inhihitors:identification of 4- [ 5- ( 4-methylphenyl ) -3- ( trifluoremethyl )- 1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem, 1997,40:1347-1365.
8Tang J, Li S, White PF, et al. Effect of parecoxib, a novel intravenous cyclooxygenuse type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology, 2002,96: 1305-1309.
9Malan TP Jr,Marsh G, Hakki SI, et al. Parecoxib sodium, a parenteral cyclooxygenuse 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology, 2003,98 :950-956.
10Kranke P, Morin AM, Roewer N, et al. Patients' global evaluation of analgesia and safety of injected parecoxib for postoperative pain: a quantitative systematic review. Anesth Analg, 2004,99:797-806.
